Want to join the conversation?
$LLY said that U.S. FDA accepted its supplemental NDA for Jardiance (empagliflozin) based on cardiovascular risk reduction data from the landmark EMPA-REG OUTCOME trial. JARDIANCE was approved by the FDA in Aug. 2014 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.